Goldman Sachs Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $26
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
Goldman Sachs analyst Salveen Richter initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Buy rating and announces Price Target of $26.
Goldman Sachs analyst Salveen Richter initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Buy rating and announces Price Target of $26.